IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Amundi

Amundi decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 31.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 878,152 shares of the medical research company’s stock after selling 409,286 shares during the quarter. Amundi’s holdings in IQVIA were worth $179,424,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Raymond James Financial Inc. acquired a new position in IQVIA in the 4th quarter valued at about $236,120,000. FMR LLC increased its holdings in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in IQVIA in the third quarter valued at approximately $147,683,000. JPMorgan Chase & Co. grew its position in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares during the period. Finally, Nordea Investment Management AB increased its stake in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 3.4 %

IQVIA stock opened at $191.69 on Monday. The stock has a market cap of $33.80 billion, a PE ratio of 25.56, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock’s fifty day moving average is $197.79 and its two-hundred day moving average is $212.63. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $261.72.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Citigroup lowered their price target on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Finally, Robert W. Baird dropped their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.